Results 51 to 60 of about 2,000 (98)

The evolving role of structural biology in pharma: integration of X‐ray crystallography, cryo‐electron microscopy and beyond

Acta Crystallographica Section D, Volume 82, Issue 6, Page 587-602, June 2026.
This review describes how an integrated structural biology platform at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, combining X‐ray crystallography, cryo‐EM, MicroED and cryo‐ET, enables seamless three‐dimensional insights from molecular to cellular length scales.
Jill E. Chrencik, Hua-Poo Su, Yacob Gomez Llorente, Rachel L. Palte, Daniel J. Klein, Robert P. Hayes, Sadie P. Antine, Guilermo A. Asmar-Rovira, Nicole Bertoletti, Noel J. Byrne, Brittany L. Carroll, Ciro D. Cordeiro, Kaylynn Curfman, James Dutko, Michael J. Eddins, Thierry Fischmann, Barani Govindarajan, Corey W. Hecksel, Thu Ho, Kaspar Hollenstein, Mee Ra Hong, Alan Hruza, Andrii Ishchenko, Maru Jaime-Garza, Matt J. Jaremko, Hayley L. Knox, James Kostas, Harini Krishnamurthy, Ioannis Manolaridis, Cameron L. Noland, Andrea T. Partridge, Sangita B. Patel, Paul Reichert, John C. Reid, Catarina Felisberto-Rodrigues, Chitra A. Shintre, Jennifer M. Shipman, Elakkiya Tamilselvan, Morgan E. Walker, Susanne N. Walker, Renjing Wang, Katharine M. Wright, Tien-Jui Yen, Byung-Kuk Yoo, Sandra B. Gabelli   +44 more
wiley   +1 more source

Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.

PLoS ONE, 2020
BACKGROUND:Cervical cancer associated with high risk-human papillomavirus (HR-HPV) infection is becoming the one of the most common female cancer in many sub-Saharan African countries. First-generation immigrant African women living in Europe are at-risk
Ralph-Sydney Mboumba Bouassa, Hélène Péré, Camélia Gubavu, Thierry Prazuck, Mohammad-Ali Jenabian, David Veyer, Jean-François Meye, Antoine Touzé, Laurent Bélec   +8 more
doaj   +1 more source

Fel d 1‐Expressing Plant‐Derived Bioparticle: A Novel Treatment for Cat Allergy

Allergy, Volume 81, Issue 6, Page 2156-2171, June 2026.
This study investigates the allergenicity and immunogenicity profile of a novel plant‐derived Fel d 1 bioparticle (eBP). Fel d 1 eBP promotes immune tolerance by redirecting allergic Th2 responses toward Th1 and IL‐10–producing regulatory pathways, including Bregs.
Janice A. Layhadi, Liliana Cifuentes Gutierrez, Sean T. Keane, William Fulton, Nichell A. Samson, Lily Y. D. Wu, Paulina Filipaviciute, Prista Hikmawati, Oleksandra Fedina, Ana Jimenez‐Gil, Stephen R. Durham, Guy Scadding, Guy Tropper, Louis‐Philippe Vézina, Patrick Colin, Ronald van Ree, Mohamed H. Shamji   +16 more
wiley   +1 more source

Cervical cancer screening adherence following initial HIV testing in Eswatini

HIV Medicine, Volume 27, Issue 6, Page 1008-1017, June 2026.
Abstract Objective Adherence to cervical cancer screening reduces cervical cancer mortality, particularly in settings with high HIV prevalence. We conducted the first nationwide study examining adherence to cervical cancer screening following first HIV testing in Eswatini, a country with the highest HIV prevalence globally.
Mpumelelo G. Ndlela, Lerato N. Vilakati, Victor Williams, Ntombifuthi M. Ginindza, Nomalanga P. Hlophe, Jason J. Liu   +5 more
wiley   +1 more source

Biopharmaceuticals for Cancer Treatment: An Update

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath, Yousuf Alam, Afsana Mustak Mim, Maksuda Akter, Mohammad Abbas Gani, Khondaker Muhammad Khairul Alam, Md. Nur Alam   +6 more
wiley   +1 more source

A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil^® in Healthy Volunteers Aged 15–35 Years

Vaccines
Background/Objectives: Human papillomavirus (HPV) infection is the leading cause of cervical cancer and is associated with several anogenital and oropharyngeal malignancies.
Erfan Pakatchian, Minoo Mohraz, Mohammad Taghavian, Babak Javadimehr, Hajar Mohammadi Barzelighi, Majid Teymoori-Rad, Mehrdad Ghodsi, Zahra Naderi Saffar   +7 more
doaj   +1 more source

Systemic Bevacizumab Therapy in Recurrent Respiratory Papillomatosis: First Preliminary Study From Azerbaijan

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 2, April 2026.
ABSTRACT Objective To report the first clinical experience from Azerbaijan using systemic bevacizumab therapy for the treatment of recurrent respiratory papillomatosis (RRP) and to evaluate its efficacy in reducing recurrence and surgical burden in both pediatric and adult patients.
Ramil Hashimli, Aynur Aliyeva
wiley   +1 more source

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, Volume 48, Issue 2, Page 259-271, April 2026.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

High‐Risk HPV in Men: A Hidden Threat to Public Health?

Reviews in Medical Virology, Volume 36, Issue 2, March 2026.
ABSTRACT High‐risk human papillomavirus (HR‐HPV) infection is a leading cause of several cancers, including those of the genital and oropharyngeal regions. While public health efforts have largely focused on women due to its link to cervical cancer, HPV also poses significant risks to men, particularly in the oropharyngeal regions. HR‐HPV prevalence in
Keesha L. Coker, Ethan L. Morgan
wiley   +1 more source

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

Cost Effectiveness and Resource Allocation, 2017
Background In Italy HPV vaccination with the quadrivalent vaccine (Gardasil®) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9®) received the European market authorization in 2015 to protect, with only
Francesco Saverio Mennini, Paolo Bonanni, Florence Bianic, Chiara de Waure, Gianluca Baio, Giacomo Plazzotta, Mathieu Uhart, Alessandro Rinaldi, Nathalie Largeron   +8 more
doaj   +1 more source